BETA DRUGS LIMITED Share Price

Beta Drugs Limited is an India-based oncology medicine manufacturing company. The Company specializes in the intricate field of complex chemical synthesis for anti-cancer bulk drugs and finished dosages. The Company operates through one segment, Pharmaceuticals. Its product category includes cosmeceutical products and oncology products. The cosmeceutical products include La’Thrix, BACINOX, URTICALM, HUMIDA, NUSPLASH, UVIREX, ADVIBE, SENSIBAR, and RECAPRO. The oncology products include Temozad(Temozolomide), ADVIN(Vinorelbine), ADSIDE(Etoposide), ADRIB(Doxorubicin), ADCOV(Leucovorin calcium), ADPLATIN(Oxaliplatin), INOTAD(Irinotecan), ADCIST(Cisplatin), ADCARB(Carboplatin), ERLOTAD(Erlotinib), ADOXI(Docetaxel), AMGICIN(Gemcitabine), ADPAXIL(Paclitaxel), ADMIDE(Bicalutamide), and others. The Company's subsidiaries include Adley Lab Limited and Adley Formulations Private Limited. As of 25 May 2026, BETA DRUGS LIMITED share price is ₹1,365.10. The stock opened at ₹1,349.40, compared to its previous close of ₹1,376.70. During today's trading session, BETA DRUGS LIMITED share price moved in the range of ₹1,349.40 to ₹1,400.00, with an average price of ₹1,374.70 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,349.40 and a high of ₹1,400.00. On the performance front, BETA DRUGS LIMITED share price has declined by 17.12% over the last six months and is down 22.22% on a year-on-year basis.

The market capitalization of BETA DRUGS LIMITED is ₹1,396 Crs, with a P/E ratio of 33.6 and a dividend yield of 0.00%.